Mavacamten
Treatment for Hypertrophic Cardiomyopathy
Typical Dosage: 5-15mg once daily
Effectiveness
85%
Safety Score
65%
Clinical Trials
31
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5-15mg once daily
Time to Effect
Weeks to 3 months
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
5(Treat 5 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
14(Treat 14 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$102,000
Monitoring:$2,000
Side Effect Mgmt:$200
Total Annual:$104,200
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$350,000/QALY
QALYs Gained
4
Outcome-Based Costs
Cost per Responder
$130,250
Comparison vs Standard of Care (Beta-blockers/CCBs + Disopyramide)
Cost Difference
+$100,000/year
More expensive
QALY Difference
+2.00 QALYs
Better outcomes
Dominance
No dominance
Active Clinical Trials
11 active trials recruiting for Mavacamten in Hypertrophic Cardiomyopathy
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
NCT07361289RECRUITING
500 participants
OBSERVATIONAL
Beijing, China +14 more
Started: Jan 15, 2026
A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06112743ACTIVE NOT RECRUITINGPHASE4
63 participants
INTERVENTIONAL
West Hollywood, United States +22 more
Started: Jan 24, 2024
A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06253221ACTIVE NOT RECRUITINGPHASE3
44 participants
INTERVENTIONAL
Birmingham, United States +46 more
Started: Apr 17, 2024
A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT06146660RECRUITING
600 participants
OBSERVATIONAL
Seoul, South Korea +1 more
Started: Jul 24, 2024
Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic Cardiomyopathy
NCT06947590ACTIVE NOT RECRUITINGNA
78 participants
INTERVENTIONAL
Shanghai, China
Started: Apr 20, 2025
Real-world Patient Reported Outcomes Among Patients Treated With Camzyos
NCT06551129RECRUITING
118 participants
OBSERVATIONAL
Boston, United States
Started: May 10, 2024
Effect of Mavacamten Treatment on Coronary Flow Reserve in oHCM
NCT06023186RECRUITING
20 participants
OBSERVATIONAL
Charlottesville, United States
Started: Nov 3, 2023
Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan
NCT07383025RECRUITING
200 participants
OBSERVATIONAL
Tokyo, Japan
Started: May 21, 2025
Mavacamten Outcomes in Hypertrophic Cardiomyopathy (HCM) and the Associated Patient and Physician Experiences in the US
NCT07557498RECRUITING
362 participants
OBSERVATIONAL
Bollington, United Kingdom
Started: Jan 15, 2026
Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07807384NOT YET RECRUITINGPHASE4
115 participants
INTERVENTIONAL
Started: Sep 1, 2026
Effectiveness and Treatment Patterns of Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan (MANAGE-HCM)
NCT07541833RECRUITING
36 participants
OBSERVATIONAL
Minato-ku, Japan
Started: Feb 5, 2026
Completed Clinical Trials
8 completed trials for Mavacamten in Hypertrophic Cardiomyopathy
Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese Subjects
NCT05135871COMPLETEDPHASE1
45 participants
INTERVENTIONAL
Shanghai, China
Started: Oct 31, 2021
A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
NCT06549608COMPLETED
683 participants
OBSERVATIONAL
Vancouver, Canada
Started: Apr 20, 2024
Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07529938COMPLETED
222 participants
OBSERVATIONAL
Zhengzhou, China
Started: Jan 1, 2024
Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER
NCT03496168COMPLETEDPHASE2
13 participants
INTERVENTIONAL
Scottsdale, United States +3 more
Started: Apr 26, 2018
A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM
NCT03723655COMPLETEDPHASE2, PHASE3
314 participants
INTERVENTIONAL
Scottsdale, United States +67 more
Started: Sep 27, 2018
A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT05414175COMPLETEDPHASE3
38 participants
INTERVENTIONAL
Uwajima, Japan +19 more
Started: Aug 19, 2022
Mavacamten in Obstructive Hypertrophic Cardiomyopathy
NCT07168655COMPLETED
163 participants
OBSERVATIONAL
Philadelphia, United States
Started: Feb 21, 2023
A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05174416COMPLETEDPHASE3
81 participants
INTERVENTIONAL
Beijing, China
Started: Jan 4, 2022
Showing 20 of 43 total trials